注射用聚己内酯微球软组织填充剂Ellansé^(■)的不良反应及处理

The Complications and Managements of Polycaprolactone-based Dermal Filler(Ellansé^(■))

聚己内酯(Polycaprolactone,PCL)微球软组织填充剂是新一代的胶原生物刺激产品,对于改善衰老引起的面部容积缺失、皱纹和面部轮廓有显著且持久的疗效。Ellansé^(■)(商品名称:伊妍仕;Sinclair医药公司,伦敦,英国)是中国目前唯一获批的PCL填充剂,其疗效和安全性已经过多项临床研究和临床实践验证。然而,随着临床应用的增加,Ellansé^(■)的不良反应也陆续被报道。由于PCL填充剂无法通过注射酶类清除,其不良反应处理具有一定挑战性。本文将PCL软组织填充剂常见不良反应的临床表现、处理方法和预防进行文献回顾和总结,包括注射部位反应、血管栓塞、结节、肉芽肿、迟发性中面部水肿和睑黄瘤样反应。

The new-generation Polycaprolactone(PCL)-based collagen stimulator(Ellansé^(■))provides a long-lasting correction of volume losses,wrinkles and contouring related to aging.So far,Ellansé®(Sinclair Pharma,London,UK)is the only PCL-based fifiller approved in China,its safety has been investigated in several clinical studies and daily clinical practice.However,as the clinical use rises,more complications may be reported.As PCL fifillers cannot be removed by injection of an enzyme,management of PCL fifiller complications is challenging.The aim of this article is to present a review of the literature regarding the clinical features,management and prevention of complications related to PCL-based collagen stimulator,including injection site reactions,intravascular injection,nodules,granulomas,late-onset edema and xanthelasma-like reaction.